Veracyte Reports Q1 2026 Financial Results
Veracyte, Inc. announced strong financial results for the first quarter of 2026, with Decipher and Afirma volume growth exceeding expectations and achieving profitability targets. CEO Marc Stapley highlighted the growing clinical evidence that differentiates the company.
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. “We had a strong start to the year, with Decipher and Afirma volume growth surpassing expectations and exceeding our profitability targets,” said Marc Stapley, Veracyte’s CEO. “Our growing clinical evidence continues to set us apart, and this quarter strengthened it even further. We believe we are approac